CA3185597A1 - Plasma kallikrein inhibitors - Google Patents
Plasma kallikrein inhibitorsInfo
- Publication number
- CA3185597A1 CA3185597A1 CA3185597A CA3185597A CA3185597A1 CA 3185597 A1 CA3185597 A1 CA 3185597A1 CA 3185597 A CA3185597 A CA 3185597A CA 3185597 A CA3185597 A CA 3185597A CA 3185597 A1 CA3185597 A1 CA 3185597A1
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- chloro
- mixture
- oxo
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063050220P | 2020-07-10 | 2020-07-10 | |
| US63/050,220 | 2020-07-10 | ||
| PCT/US2021/040420 WO2022010828A1 (en) | 2020-07-10 | 2021-07-06 | Plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3185597A1 true CA3185597A1 (en) | 2022-01-13 |
Family
ID=79552050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3185597A Pending CA3185597A1 (en) | 2020-07-10 | 2021-07-06 | Plasma kallikrein inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12528786B2 (enExample) |
| EP (1) | EP4178620B1 (enExample) |
| JP (1) | JP7773522B2 (enExample) |
| KR (1) | KR20230038526A (enExample) |
| CN (1) | CN116157154B (enExample) |
| AU (1) | AU2021306250A1 (enExample) |
| CA (1) | CA3185597A1 (enExample) |
| MX (1) | MX2023000507A (enExample) |
| WO (1) | WO2022010828A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4210694B1 (en) * | 2020-09-10 | 2025-10-15 | Merck Sharp & Dohme LLC | Plasma kallikrein inhibitors |
| WO2024173196A1 (en) * | 2023-02-17 | 2024-08-22 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
| WO2026096331A1 (en) * | 2024-10-30 | 2026-05-07 | Merck Sharp & Dohme Llc | Plasma kallikrein inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8609866B2 (en) | 2009-12-18 | 2013-12-17 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
| HRP20221373T1 (hr) | 2014-03-07 | 2023-01-06 | Biocryst Pharmaceuticals, Inc. | Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi |
| KR102286305B1 (ko) | 2014-07-16 | 2021-08-09 | 라이프에스씨아이 파마슈티컬스, 인크. | 치료적 억제 화합물 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| WO2017001926A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc | Therapeutic inhibitory compounds |
| WO2017072020A1 (en) * | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| US10640486B2 (en) * | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| BR112018008506B8 (pt) | 2015-10-29 | 2023-12-05 | Merck Sharp & Dohme | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos |
| EP3612523B1 (en) | 2017-04-21 | 2021-06-09 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| CN113039181B (zh) * | 2018-08-16 | 2024-08-13 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的杂芳族甲酰胺衍生物 |
| KR102931248B1 (ko) * | 2020-06-16 | 2026-03-03 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
-
2021
- 2021-07-06 EP EP21837278.7A patent/EP4178620B1/en active Active
- 2021-07-06 US US18/014,787 patent/US12528786B2/en active Active
- 2021-07-06 CN CN202180055135.6A patent/CN116157154B/zh active Active
- 2021-07-06 AU AU2021306250A patent/AU2021306250A1/en active Pending
- 2021-07-06 CA CA3185597A patent/CA3185597A1/en active Pending
- 2021-07-06 KR KR1020237004707A patent/KR20230038526A/ko not_active Withdrawn
- 2021-07-06 MX MX2023000507A patent/MX2023000507A/es unknown
- 2021-07-06 WO PCT/US2021/040420 patent/WO2022010828A1/en not_active Ceased
- 2021-07-06 JP JP2023500332A patent/JP7773522B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN116157154A (zh) | 2023-05-23 |
| US12528786B2 (en) | 2026-01-20 |
| KR20230038526A (ko) | 2023-03-20 |
| WO2022010828A1 (en) | 2022-01-13 |
| EP4178620A1 (en) | 2023-05-17 |
| AU2021306250A1 (en) | 2023-02-16 |
| EP4178620A4 (en) | 2024-08-07 |
| JP7773522B2 (ja) | 2025-11-19 |
| CN116157154B (zh) | 2026-05-01 |
| US20230348428A1 (en) | 2023-11-02 |
| EP4178620B1 (en) | 2026-04-01 |
| JP2023533519A (ja) | 2023-08-03 |
| MX2023000507A (es) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170044183A1 (en) | FACTOR XIa INHIBITORS | |
| JP7787890B2 (ja) | 血漿カリクレイン阻害剤 | |
| EP4178620B1 (en) | Plasma kallikrein inhibitors | |
| EP4210694B1 (en) | Plasma kallikrein inhibitors | |
| EP3229801B1 (en) | Factor ixa inhibitors | |
| CA3182626A1 (en) | Plasma kallikrein inhibitors | |
| JP7794991B2 (ja) | 血漿カリクレイン阻害薬 | |
| WO2024173196A1 (en) | Plasma kallikrein inhibitors | |
| EP4308125B1 (en) | Plasma kallikrein inhibitors | |
| RU2849957C1 (ru) | Ингибиторы калликреина плазмы | |
| EP4326274B1 (en) | Plasma kallikrein inhibitors | |
| RU2854493C2 (ru) | Ингибиторы калликреина плазмы | |
| RU2852935C1 (ru) | Ингибиторы калликреина плазмы | |
| WO2026096331A1 (en) | Plasma kallikrein inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250530 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250530 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250602 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250602 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250616 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260616 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260616 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260709 |